Hyperpigmentation Disorders Treatment Market by Treatment Type (Topical Drugs, Chemical Peels, Phototherapy, Laser Therapy, and Microdermabrasion), Disease Indication (Melasma, Solar Lentigines, and Post-inflammatory Hyperpigmentation), End User (Dermatology Centers, Aesthetic Clinics, and Hospitals) - Analysis & Forecast 2019-2030
Report ID : 36 | Published Date : Feb 2019 | Pages : 150 | Region : Global | Report Code : MD-19
Hyperpigmentation Disorders Treatment Market Overview and Introduction
The report, the global hyperpigmentation disorders treatment market is estimated to be over US$ 3.5 Bn in 2017. It is anticipated to grow at a substantial CAGR from 2019 to 2030.The global hyperpigmentation disorders treatment market is segmented by treatment type, disease indication, end user and region.
Hyperpigmentation is a skin condition, where the skin turns dark in patches as compared to its normal surrounding skin. In most cases, formation of such patches occur due to the accumulation of excess of melanin, a brownish pigment responsible for normal skin color. The condition of hyperpigmentation is known to affect people from all races.
The global hyperpigmentation disorders treatment market is driven by technological advancements in the pigmentation treatment and therapy arena, increasing patient awareness and health care expenditure, and rising geriatric population. Rising adoption of minimally invasive procedure, increasing medical tourism for aesthetics has been crucial in contributing to increasing growth of the hyperpigmentation disorders treatment market. However, high cost, complications & risk associated with medical aesthetics products and treatment is likely to restrain the market to a certain extent.
Hyperpigmentation Disorders Treatment Market by Treatment Type
On the basis of type, the hyperpigmentation disorders treatment market is segmented into topical drugs, chemical peels, phototherapy, laser therapy, microdermabrasion and other treatments. The segment of topical drugs is anticipated to account for the largest share in the hyperpigmentation disorders treatments market, owing to widescale prescription of topical treatment options by dermatologists worldwide.
Hyperpigmentation Disorders Treatment Market by Disease Indication
The segment of disease indication can be segmented into melasma, solar lentigines, post-inflammatory hyperpigmentation and other indications. Melasma segment is constituted a substantial share in 2018, owing to increasing incidences of this contidion as compared to other indications.
Hyperpigmentation Disorders Treatment Market by End User
Finally, on the basis of end user, the hyperpigmentation disorders treatments market is segmented into dermatology centers, aesthetic clinics, and hospitals, and other end user.
Hyperpigmentation Disorders Treatment Market by Regions
The global hyperpigmentation disorders treatment market can be segmented into North America, Europe, Asia Pacific, and Rest of World (ROW). North America dominated the market of hyperpigmentation disorders treatment, followed by Europe and Asia Pacific. Asia Pacific will continue to dominate the global hyperpigmentation disorders treatments market in the forecast period owing to factors such as growing adoption of minimally-invasive procedures, rising consciousness regarding ones looks and highly developed healthcare system. However, Asia Pacific is expected to witness the highest CAGR, with the growth in this market centered at China, India, and Japan. Factors such as the rising focus of major players in emerging Asian countries, penetration and adoption of latest technologies, increasing disposable incomes and growing government support are driving the growth of the hyperpigmentation disorders treatments market in this region.
Hyperpigmentation Disorders Treatment Market Prominent Players
The prominent players in the global Hyperpigmentation Disorders Treatments market are Bayer AG, RXi Pharmaceuticals, ALLERGAN, Galderma laboratories, SkinCeuticals International, PIERRE FABRE GROUP, EpiPharm AG, Obagi Cosmeceuticals LLC., and VIVIERPHARMA among others.